Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Cardiovascular Systems Launches the Take A Stand Against Amputation Program in Time for September Peripheral Artery Disease (PAD) Awareness Month 09/01/16
September marks Peripheral Artery Disease (PAD) Awareness Month. Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), has launched a public awareness and patient advocacy program, Take A Stand Against Amputation, to provide education about the disease and treatment options. Up to a staggering 18 million Americans1 suffer from this potentially life-threatening disease. According to the American Heart Association, PAD patients have a six to seven times greater risk of coronary artery disease, heart attack and stroke than the rest of the population. If left untreated, those who suffer from PAD are at risk of serious consequences. In fact, each year 160,000 to 180,000 Americans undergo amputation of a limb as a result of complications associated with peripheral artery disease (PAD)2. Of those suffering from PAD, up to 3.5 million have progressed to critical limb ischemia (CLI) 3 , the most severe and potentially deadly form of PAD, where the blood vessels become dangerously narrow, leading...
More >>
Cardiovascular Systems Names Scott Ward as CEO 08/16/16
Interim Leader and Industry Veteran to Assume Permanent Post Immediately Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), today announced that, following a national search, it has named Scott R. Ward, 56, the company’s new Chairman and Chief Executive Officer, effective immediately. Ward has been serving as Chairman since November 2014 and Interim President and Chief Executive Officer since November 2015. He joined CSI’s board in 2013. Edward Brown, a member of CSI’s board since 2009, has been appointed as CSI’s Lead Independent Director. “As a Director, Scott brings invaluable leadership and industry expertise to this organization,” said Leslie Trigg , Chair of CSI’s Governance/ Nominating Committee. “His knowledge of the company runs deep as does his commitment to its success. We look forward to supporting Scott in this new role.” Said Ward, “I am pleased with the progress CSI has made to improve the quality of care for patients with coronary and peripheral artery disease. However,...
More >>

Upcoming Events

No items found